---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-089270"
form_type: "8-K"
ticker: null
cik: "0001923840"
company_name: "Third Harmonic Bio, Inc."
filed_at: "2025-04-22T23:59:59+00:00"
generated_at: "2026-05-23T09:37:33.800536+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Third Harmonic Bio CSO Christopher Dinsmore steps down effective April 21, 2025

## Summary
- Christopher Dinsmore resigned as Chief Scientific Officer on April 21, 2025.
- He will receive a lump-sum severance of 9 months' salary and healthcare cost coverage for up to 9 months.
- Separation agreement includes release of claims, non-disparagement, and confidentiality provisions.
- No successor has been announced; Dinsmore's departure leaves the CSO role vacant.
- Severance benefits are contingent on compliance with the separation agreement.

## SEC filing metadata
- accession: 0001193125-25-089270
- form_type: 8-K
- cik: 0001923840
- company_name: Third Harmonic Bio, Inc.
- filed_at: 2025-04-22T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1923840/000119312525089270/0001193125-25-089270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1923840/000119312525089270/d829877d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-089270
- JSON: https://secwatch.observer/filing/0001193125-25-089270.json
- Plain text: https://secwatch.observer/filing/0001193125-25-089270.txt

## Key facts
- Executive change
  Christopher Dinsmore resigned as Chief Scientific Officer at Third Harmonic Bio, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On April 21, 2025, Third Harmonic Bio, Inc. (the “ Company ”) and Christopher Dinsmore, Chief Scientific Officer of the Company, entered into a separation agreement with the Company (the “ Separation Agreement ”), pursuant to which Dr. Dinsmore would step down as Chief Scientific Officer effective April 21, 2025 (the “ Separation Date ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1923840/000119312525089270/0001193125-25-089270-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.